LAA Closure vs. Medical Therapy: New Insights from CLOSURE-AF

For high-risk patients with Atrial Fibrillation (AFib), choosing the right stroke prevention strategy is a delicate balance. The recently published CLOSURE-AF trial in the New England Journal of Medicine provides critical clarity on whether Left Atrial Appendage (LAA) closure is a viable alternative to standard medical care for this specific group.

The Study at a Glance

The trial, detailed by the American College of Cardiology, followed 912 older patients (average age 78) who faced a high risk for both stroke and major bleeding. Participants were randomized to receive either a catheter-based LAA closure device or physician-directed medical therapy, which typically included direct oral anticoagulants.

Key Findings

• Noninferiority Not Met: The study found that LAA closure was not noninferior to medical therapy regarding the composite endpoint of stroke, systemic embolism, or death.

• Complication Risks: While the device was successfully implanted in 98% of cases, 6% of patients suffered periprocedural complications, including pericardial tamponade and major bleeding.

• Standard of Care: The results suggest that for older, high-risk patients, individualized medical therapy remains the preferred standard over catheter-based interventions.

As noted by study authors, this vulnerable patient group is particularly prone to early complications, making the "theoretical promise" of the device difficult to realize in clinical practice.